FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149797825> ?p ?o ?g. }

• W2149797825 endingPage "109" @default.
• W2149797825 startingPage "103" @default.
• W2149797825 abstract "To assess the most important features and clinical impact of pleural effusions, which are a common toxicity during dasatinib treatment and often impair its high efficacy, 172 unselected consecutive patients with chronic myelogenous leukaemia in chronic phase treated in 27 Italian centres, with dasatinib when aged >60 years for resistance/intolerance to imatinib, were examined. During treatment, 52/172 patients (30.2%) presented pleural effusion, which was grades 1–2 in 38 patients and grades 3–4 in 14 patients (8.1% of the entire cohort of patients), according to the WHO scale; in 14/52 patients (26.9%), there was a concomitant pericardial effusion. Pleural effusion was recurrent in 25/52 patients (48.0%). Median time from dasatinib to first pleural effusion was 11.0 months (interquartile range 3.6–18.6). Eleven patients (6.4%) required permanent dasatinib discontinuation. Only presence of concomitant pulmonary disease ( p = 0.035) and initial daily dose of dasatinib (140 mg vs 100 mg, p = 0.014) were significantly associated with pleural effusions. There were no differences among patients with or without pleural effusions as concerns response rates and overall survival. Pleural effusions were common in our unselected ‘real-life’ population of elderly patients but were clinically manageable and did not seem to affect treatment results. Copyright © 2012 John Wiley & Sons, Ltd." @default.
• W2149797825 created "2016-06-24" @default.
• W2149797825 creator A5006023644 @default.
• W2149797825 creator A5006110055 @default.
• W2149797825 creator A5006810419 @default.
• W2149797825 creator A5006854942 @default.
• W2149797825 creator A5008040655 @default.
• W2149797825 creator A5018509851 @default.
• W2149797825 creator A5020333760 @default.
• W2149797825 creator A5026992937 @default.
• W2149797825 creator A5028913158 @default.
• W2149797825 creator A5030471947 @default.
• W2149797825 creator A5031714115 @default.
• W2149797825 creator A5035566807 @default.
• W2149797825 creator A5036480527 @default.
• W2149797825 creator A5043599930 @default.
• W2149797825 creator A5044869604 @default.
• W2149797825 creator A5074895768 @default.
• W2149797825 creator A5078324992 @default.
• W2149797825 creator A5080326016 @default.
• W2149797825 creator A5089760320 @default.
• W2149797825 creator A5090108654 @default.
• W2149797825 date "2012-07-19" @default.
• W2149797825 modified "2023-10-16" @default.
• W2149797825 title "Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia" @default.
• W2149797825 cites W1970962784 @default.
• W2149797825 cites W1975743727 @default.
• W2149797825 cites W1981809014 @default.
• W2149797825 cites W1987060661 @default.
• W2149797825 cites W2010901133 @default.
• W2149797825 cites W2068192260 @default.
• W2149797825 cites W2080125373 @default.
• W2149797825 cites W2082751900 @default.
• W2149797825 cites W2084397515 @default.
• W2149797825 cites W2097799776 @default.
• W2149797825 cites W2097946794 @default.
• W2149797825 cites W2101635775 @default.
• W2149797825 cites W2116153687 @default.
• W2149797825 cites W2120222130 @default.
• W2149797825 cites W2133911206 @default.
• W2149797825 cites W2148743957 @default.
• W2149797825 cites W2151486690 @default.
• W2149797825 cites W2168782870 @default.
• W2149797825 cites W2168833663 @default.
• W2149797825 doi "https://doi.org/10.1002/hon.2020" @default.
• W2149797825 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22815278" @default.
• W2149797825 hasPublicationYear "2012" @default.
• W2149797825 type Work @default.
• W2149797825 sameAs 2149797825 @default.
• W2149797825 citedByCount "51" @default.
• W2149797825 countsByYear W21497978252013 @default.
• W2149797825 countsByYear W21497978252014 @default.
• W2149797825 countsByYear W21497978252015 @default.
• W2149797825 countsByYear W21497978252016 @default.
• W2149797825 countsByYear W21497978252017 @default.
• W2149797825 countsByYear W21497978252018 @default.
• W2149797825 countsByYear W21497978252019 @default.
• W2149797825 countsByYear W21497978252020 @default.
• W2149797825 countsByYear W21497978252021 @default.
• W2149797825 countsByYear W21497978252022 @default.
• W2149797825 countsByYear W21497978252023 @default.
• W2149797825 crossrefType "journal-article" @default.
• W2149797825 hasAuthorship W2149797825A5006023644 @default.
• W2149797825 hasAuthorship W2149797825A5006110055 @default.
• W2149797825 hasAuthorship W2149797825A5006810419 @default.
• W2149797825 hasAuthorship W2149797825A5006854942 @default.
• W2149797825 hasAuthorship W2149797825A5008040655 @default.
• W2149797825 hasAuthorship W2149797825A5018509851 @default.
• W2149797825 hasAuthorship W2149797825A5020333760 @default.
• W2149797825 hasAuthorship W2149797825A5026992937 @default.
• W2149797825 hasAuthorship W2149797825A5028913158 @default.
• W2149797825 hasAuthorship W2149797825A5030471947 @default.
• W2149797825 hasAuthorship W2149797825A5031714115 @default.
• W2149797825 hasAuthorship W2149797825A5035566807 @default.
• W2149797825 hasAuthorship W2149797825A5036480527 @default.
• W2149797825 hasAuthorship W2149797825A5043599930 @default.
• W2149797825 hasAuthorship W2149797825A5044869604 @default.
• W2149797825 hasAuthorship W2149797825A5074895768 @default.
• W2149797825 hasAuthorship W2149797825A5078324992 @default.
• W2149797825 hasAuthorship W2149797825A5080326016 @default.
• W2149797825 hasAuthorship W2149797825A5089760320 @default.
• W2149797825 hasAuthorship W2149797825A5090108654 @default.
• W2149797825 hasConcept C119060515 @default.
• W2149797825 hasConcept C126322002 @default.
• W2149797825 hasConcept C141071460 @default.
• W2149797825 hasConcept C2776960273 @default.
• W2149797825 hasConcept C2777583451 @default.
• W2149797825 hasConcept C2778461978 @default.
• W2149797825 hasConcept C2778715236 @default.
• W2149797825 hasConcept C2778729363 @default.
• W2149797825 hasConcept C2779384505 @default.
• W2149797825 hasConcept C2779536868 @default.
• W2149797825 hasConcept C2779634585 @default.
• W2149797825 hasConcept C71924100 @default.
• W2149797825 hasConcept C90924648 @default.
• W2149797825 hasConceptScore W2149797825C119060515 @default.
• W2149797825 hasConceptScore W2149797825C126322002 @default.
• W2149797825 hasConceptScore W2149797825C141071460 @default.

• next